JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blaya, C.
Right arrow Articles by Alino, S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blaya, C.
Right arrow Articles by Alino, S. F.

Anti-interleukin 4 antibody and indomethacin synergistic effect on B16 melanoma tumor progression

C Blaya, J Crespo, A Crespo and SF Alino

Department of Pharmacology, Faculty of Medicine, University of Valencia, Spain.

B16 melanoma-bearing mice were treated with anti-interleukin 4 antibody, indomethacin or its combination to evaluate the ability of the primary tumor to induce lung metastasis and the antitumor host response. Flow cytometry of tumor cells incubated with sera from tumor- bearing mice showed B16 melanoma to induce a significant antitumor humoral response (39.0 +/- 1.1% positive cells versus 1.8 +/- 0.9% in the control). The treatment of tumor-bearing mice with antimouse anti- interleukin 4 monoclonal antibody plus indomethacin significantly increased (P < .01) the mean value of lung metastasis (from 6.1 +/- 3.0 in the controls to 50.8 +/- 21.8). Also, a significant increase in natural cytotoxicity against tumor cells was observed when both peripheral blood mononuclear cells and splenocytes were used as effector cells. In contrast, an antibody-dependent cellular cytotoxicity decrease was found with effector cells from both normal and tumor-bearing mice. In the former, the antibody-dependent cellular cytotoxicity decrease was 49.4% and 58.4% (P < .05) for peripheral blood mononuclear cells and splenocytes, whereas in the second case the decrease was 40.7% (P < .05) and 29.1% (P < .01), respectively. These results suggest that an efficient antibody-dependent cellular cytotoxicity response might be necessary to secure an effective host antitumor immune response.

Volume 279, Issue 2, pp. 472-477, 11/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
D. A. Maria, O. G. Ribeiro, K. F. Pizzocaro, M. De Franco, W. K. Cabrera, N. Starobinas, V. Gallois, M. Siqueira, M. Seman, and O. M. Ibanez
Resistance to melanoma metastases in mice selected for high acute inflammatory response
Carcinogenesis, February 1, 2001; 22(2): 337 - 342.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Bohm, S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann
T Cell-Mediated, IFN-{gamma}-Facilitated Rejection of Murine B16 Melanomas
J. Immunol., July 15, 1998; 161(2): 897 - 908.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics.